Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy progress and prospects: reprograming gene expression by trans-splicing.

L G Mitchell1, G J McGarrity

  • 1Intronn Inc., Gaithersburg, MD 20878, USA.

Gene Therapy
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.

Journal of thrombosis and haemostasis : JTH·2017
Same author

The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.

Blood cells, molecules & diseases·2017
Same author

The day of elias.

Perspectives in biology and medicine·2015
Same author

Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis: discussion.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.

Klinische Padiatrie·2010

RNA trans-splicing reprograms gene sequences to create new products, offering advantages over gene therapy. This technology enables precise gene editing and correction of genetic mutations for therapeutic applications.

Area of Science:

  • Molecular Biology
  • Genetic Engineering
  • RNA Therapeutics

Background:

  • Trans-splicing involves combining RNA or protein molecules to create chimeric products.
  • RNA trans-splicing modifies endogenous messenger RNA (mRNA) or pre-mRNA sequences.
  • This technology has diverse applications based on inserted sequences.

Purpose of the Study:

  • To explore the mechanisms and applications of RNA trans-splicing.
  • To highlight the advantages of trans-splicing RNA therapy over conventional gene therapy.

Main Methods:

  • Utilizing platform technologies for RNA or protein molecule combination.
  • Reprogramming endogenous mRNA or pre-mRNA sequences.

Main Results:

Related Experiment Videos

  • Generation of new, desired gene products through chimeric molecule formation.
  • Demonstration of broad applicability based on sequence insertion and targeting.

    • Conclusions:

    • Trans-splicing RNA therapy provides enhanced control over gene expression compared to traditional gene therapy.
    • Advantages include reduced ectopic expression, use of smaller constructs, and correction of dominant-negative mutations.